179 related articles for article (PubMed ID: 28013014)
1. Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.
Johnpulle RA; Paczesny S; Jung DK; Daguindau E; Jagasia MH; Savani BN; Chinratanalab W; Cornell RF; Goodman S; Greer JP; Kassim AA; Sengsayadeth S; Byrne MT; Engelhardt BG
Biol Blood Marrow Transplant; 2017 Mar; 23(3):529-532. PubMed ID: 28013014
[TBL] [Abstract][Full Text] [Related]
2. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
3. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
4. New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.
Engelhardt BG; Savani U; Jung DK; Powers AC; Jagasia M; Chen H; Winnick JJ; Tamboli RA; Crowe JE; Abumrad NN
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1225-1231. PubMed ID: 30738170
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation.
Griffith ML; Jagasia MH; Misfeldt AA; Chen H; Engelhardt BG; Kassim A; Savani BN; Survant M; Jagasia SM
Biol Blood Marrow Transplant; 2011 Jan; 17(1):86-92. PubMed ID: 20561594
[TBL] [Abstract][Full Text] [Related]
6. The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the Myocardium.
Tseng CCS; Huibers MMH; van Kuik J; de Weger RA; Vink A; de Jonge N
J Cardiovasc Transl Res; 2018 Feb; 11(1):15-21. PubMed ID: 29285671
[TBL] [Abstract][Full Text] [Related]
7. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
8. Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity.
Schachtner T; Stein M; Reinke P
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28423197
[TBL] [Abstract][Full Text] [Related]
9. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
Majhail NS; Challa TR; Mulrooney DA; Baker KS; Burns LJ
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
[TBL] [Abstract][Full Text] [Related]
10. Multiple functional variants in the
Karaesmen E; Hahn T; Dile AJ; Rizvi AA; Wang J; Wang T; Haagenson MD; Preus L; Zhu Q; Liu Q; Yan L; Liu S; Haiman CA; Stram D; Pooler L; Sheng X; Van Den Berg D; Brock G; Webb A; McCarthy PL; Pasquini MC; Spellman SR; Lee SJ; Paczesny S; Sucheston-Campbell LE
Blood Adv; 2019 Aug; 3(16):2512-2524. PubMed ID: 31455667
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity.
Engelhardt BG; Jagasia SM; Crowe JE; Griffith ML; Savani BN; Kassim AA; Lu P; Weitkamp JH; Moore DJ; Yoder SM; Rock MT; Jagasia M
Blood; 2012 Mar; 119(10):2417-21. PubMed ID: 22262764
[TBL] [Abstract][Full Text] [Related]
13. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
Fuji S; Rovó A; Ohashi K; Griffith M; Einsele H; Kapp M; Mohty M; Majhail NS; Engelhardt BG; Tichelli A; Savani BN
Bone Marrow Transplant; 2016 Aug; 51(8):1041-9. PubMed ID: 27042848
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects.
Cardellini M; Rizza S; Casagrande V; Cardolini I; Ballanti M; Davato F; Porzio O; Canale MP; Legramante JM; Mavilio M; Menghini R; Martelli E; Farcomeni A; Federici M
Acta Diabetol; 2019 Mar; 56(3):273-280. PubMed ID: 30259114
[TBL] [Abstract][Full Text] [Related]
15. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM).
Kuypers DR; Claes K; Bammens B; Evenepoel P; Vanrenterghem Y
Nephrol Dial Transplant; 2008 Jun; 23(6):2033-42. PubMed ID: 18174264
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?
Choi JY; Kwon OJ
Transplant Proc; 2013 Oct; 45(8):2892-8. PubMed ID: 24156999
[TBL] [Abstract][Full Text] [Related]
17. The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery.
Demyanets S; Kaun C; Kaider A; Speidl W; Prager M; Oravec S; Hohensinner P; Wojta J; Rega-Kaun G
Cardiovasc Diabetol; 2020 Feb; 19(1):26. PubMed ID: 32101157
[TBL] [Abstract][Full Text] [Related]
18. Differential Association between Blood Glucose Levels and Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation Based on Presence or Absence of Preexisting Diabetes.
Rashid N; Gooley T; Boeckh M; Oshima MU; Chao JH; Hirsch IB; Mielcarek M
Transplant Cell Ther; 2024 Apr; 30(4):417.e1-417.e9. PubMed ID: 38242443
[TBL] [Abstract][Full Text] [Related]
19. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
Pusceddu I; Dieplinger B; Mueller T
Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
[TBL] [Abstract][Full Text] [Related]
20. The risk factors for diabetes mellitus after kidney transplantation.
Razeghi E; Heydarian P; Amerian M; Pourmand G
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1038-43. PubMed ID: 21060170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
